Novartis witnessed a partial recovery in Q3 largely (and surprisingly) driven by the non-oncology portfolio. Nevertheless, the group reported healthy Q3 operating profit improvements and also upgraded its full-year profitability guidance. While re-emerging COVID-19 lockdown risks can (further) de-rail near-term momentum, the recent share price sell-off opens an attractive investment window, especially considering the unchanged potential of the pipeline assets across therapeutic and newer/innovat ....
